NIKKEI 225
37,138.19 -941.51 (-2.47%) HANG SENG
16,184.02 -201.85 (-1.23%) CRUDE OIL
84.47 +1.74 (+2.10%) GOLD FUTURES
2,399.90 +1.90 (+0.08%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,219.32 +574.16 (+1.16%)
Enanta Pharmaceuticals, Inc. (9EP.F)
| Previous close | 12.90 |
| Open | 13.10 |
| Bid | 12.30 x 15600 |
| Ask | 12.60 x 15300 |
| Day's range | 12.20 - 13.10 |
| 52-week range | 7.50 - 34.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 258.103M |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.19 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 65.33 |
Business WireEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
WATERTOWN, Mass., April 17, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.
Business WireEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
WATERTOWN, Mass., March 06, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m. ET in Miami, FL.
Simply Wall St.Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
The analysts might have been a bit too bullish on Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ), given that the company...
